Cargando…
Pulmonary fibrosis: pathogenesis, etiology and regulation
Pulmonary fibrosis and architectural remodeling of tissues can severely disrupt lung function, often with fatal consequences. The etiology of pulmonary fibrotic diseases is varied, with an array of triggers including allergens, chemicals, radiation and environmental particles. However, the cause of...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
© Society for Mucosal Immunology. Published by Elsevier Inc.
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2675823/ https://www.ncbi.nlm.nih.gov/pubmed/19129758 http://dx.doi.org/10.1038/mi.2008.85 |
_version_ | 1782166715823554560 |
---|---|
author | Wilson, M S Wynn, T A |
author_facet | Wilson, M S Wynn, T A |
author_sort | Wilson, M S |
collection | PubMed |
description | Pulmonary fibrosis and architectural remodeling of tissues can severely disrupt lung function, often with fatal consequences. The etiology of pulmonary fibrotic diseases is varied, with an array of triggers including allergens, chemicals, radiation and environmental particles. However, the cause of one of the most common pulmonary fibrotic conditions, idiopathic pulmonary fibrosis (IPF), is still unclear. This review examines common mechanisms of pulmonary wound-healing responses following lung injury, and highlights the pathogenesis of some of the most widespread pulmonary fibrotic diseases. A three phase model of wound repair is reviewed that includes; (1) injury; (2) inflammation; and (3) repair. In most pulmonary fibrotic conditions dysregulation at one or more of these phases has been reported. Chronic inflammation can lead to an imbalance in the production of chemokines, cytokines, growth factors, and disrupt cellular recruitment. These changes coupled with excessive pro-fibrotic IL-13 and/or TGFβ1 production can turn a well-controlled healing response into a pathogenic fibrotic response. Endogenous regulatory mechanisms are discussed including novel areas of therapeutic intervention. Restoring homeostasis to these dysregulated healing responses, or simply neutralizing the key pro-fibrotic mediators may prevent or slow the progression of pulmonary fibrosis. |
format | Text |
id | pubmed-2675823 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | © Society for Mucosal Immunology. Published by Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-26758232010-03-01 Pulmonary fibrosis: pathogenesis, etiology and regulation Wilson, M S Wynn, T A Mucosal Immunol Article Pulmonary fibrosis and architectural remodeling of tissues can severely disrupt lung function, often with fatal consequences. The etiology of pulmonary fibrotic diseases is varied, with an array of triggers including allergens, chemicals, radiation and environmental particles. However, the cause of one of the most common pulmonary fibrotic conditions, idiopathic pulmonary fibrosis (IPF), is still unclear. This review examines common mechanisms of pulmonary wound-healing responses following lung injury, and highlights the pathogenesis of some of the most widespread pulmonary fibrotic diseases. A three phase model of wound repair is reviewed that includes; (1) injury; (2) inflammation; and (3) repair. In most pulmonary fibrotic conditions dysregulation at one or more of these phases has been reported. Chronic inflammation can lead to an imbalance in the production of chemokines, cytokines, growth factors, and disrupt cellular recruitment. These changes coupled with excessive pro-fibrotic IL-13 and/or TGFβ1 production can turn a well-controlled healing response into a pathogenic fibrotic response. Endogenous regulatory mechanisms are discussed including novel areas of therapeutic intervention. Restoring homeostasis to these dysregulated healing responses, or simply neutralizing the key pro-fibrotic mediators may prevent or slow the progression of pulmonary fibrosis. © Society for Mucosal Immunology. Published by Elsevier Inc. 2009-03 2022-12-31 /pmc/articles/PMC2675823/ /pubmed/19129758 http://dx.doi.org/10.1038/mi.2008.85 Text en Copyright © 2009 © Society for Mucosal Immunology. Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Wilson, M S Wynn, T A Pulmonary fibrosis: pathogenesis, etiology and regulation |
title | Pulmonary fibrosis: pathogenesis, etiology and regulation |
title_full | Pulmonary fibrosis: pathogenesis, etiology and regulation |
title_fullStr | Pulmonary fibrosis: pathogenesis, etiology and regulation |
title_full_unstemmed | Pulmonary fibrosis: pathogenesis, etiology and regulation |
title_short | Pulmonary fibrosis: pathogenesis, etiology and regulation |
title_sort | pulmonary fibrosis: pathogenesis, etiology and regulation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2675823/ https://www.ncbi.nlm.nih.gov/pubmed/19129758 http://dx.doi.org/10.1038/mi.2008.85 |
work_keys_str_mv | AT wilsonms pulmonaryfibrosispathogenesisetiologyandregulation AT wynnta pulmonaryfibrosispathogenesisetiologyandregulation |